Loading stock data…
$26.23-0.43 (-1.61%)
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.
Maze Therapeutics, Inc. in the Healthcare sector is trading at $26.50 with a market capitalization of $1.3B. Wall Street consensus targets $61.50 (12 analysts), implying a +132.1% move over the next 12 months. The stock is currently near its 52-week low of $21.95, remaining 18.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $20.00M | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$48.03M↓ | -$26.55M↑ | -$38.06M↓ | -$32.97M↑ | -$36.47M |
| Net Income | -$44.73M↓ | -$24.21M↑ | -$34.57M↓ | -$30.09M↑ | -$33.68M |
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibit...